Channelpedia

PubMed 24583250


Referenced in Channelpedia wiki pages of: none

Automatically associated channels: HCN2 , HCN3 , HCN4



Title: I(f) blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytes.

Authors: Susanne Scheruebel, Chintan N Koyani, Seth Hallström, Petra Lang, Dieter Platzer, Heinrich Mächler, Karl Lohner, Ernst Malle, Klaus Zorn-Pauly, Brigitte Pelzmann

Journal, date & volume: J. Mol. Cell. Cardiol., 2014 Jul , 72, 64-73

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/24583250


Abstract
Lower heart rate is associated with better survival in patients with multiple organ dysfunction syndrome (MODS), a disease mostly caused by sepsis. The benefits of heart rate reduction by ivabradine during MODS are currently being investigated in the MODIfY clinical trial. Ivabradine is a selective inhibitor of the pacemaker current If and since If is impaired by lipopolysaccharide (LPS, endotoxin), a trigger of sepsis, we aimed to explore If blocking potency of ivabradine under elevated endotoxin levels in human atrial cardiomyocytes. Treatment of myocytes with S-LPS (containing the lipid A moiety, a core oligosaccharide and an O-polysaccharide chain) but not R595 (an O-chain lacking LPS-form) caused If inhibition under acute and chronic septic conditions. The specific interaction of S-LPS but not R595 to pacemaker channels HCN2 and HCN4 proves the necessity of O-chain for S-LPS-HCN interaction. The efficacy of ivabradine to block If was reduced under septic conditions, an observation that correlated with lower intracellular ivabradine concentrations in S-LPS- but not R595-treated cardiomyocytes. Computational analysis using a sinoatrial pacemaker cell model revealed that despite a reduction of If under septic conditions, ivabradine further decelerated pacemaking activity. This novel finding, i.e. If inhibition by ivabradine under elevated endotoxin levels in vitro, may provide a molecular understanding for the efficacy of this drug on heart rate reduction under septic conditions in vivo, e.g. the MODIfY clinical trial.